Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

被引：0
|
作者：
W C Stewart
D G Day
J A Stewart
K T Holmes
J N Jenkins
机构：
[1] Pharmaceutical Research Network,
[2] LLC,undefined
[3] Carolina Eye Institute at the University of South Carolina,undefined
[4] School of Medicine,undefined
[5] Atlanta Research Company,undefined
来源：
Eye | 2004年 / 18卷
关键词：
ocular tolerability; dorzolamide; brinzolamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose To compare ocular tolerability of dorzolamide 2%, brinzolamide 1%, and placebo given three times daily.
引用
收藏
页码：905 / 910
页数：5
相关论文
共 50 条
  • [31] The Safety and Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 2%/Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension
    Manni, Gianluca
    Denis, Phillipe
    Chew, Paul
    Sharpe, Elisabeth D.
    Orengo-Nania, Silvia
    Coote, Michael A.
    Laganovska, Guna
    Volksone, Lasma
    Zeyen, Thierry
    Filatori, Isabella
    James, John
    Aung, Tin
    JOURNAL OF GLAUCOMA, 2009, 18 (04) : 293 - 300
  • [32] The Safety and Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 2%/Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension
    Akcay, Betul Ilkay Sezgin
    Guney, Esra
    Bozkurt, Kansu Tahir
    Unlu, Cihan
    Akcali, Gulunay
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (10) : 882 - 886
  • [33] The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) as a primary therapy in patients with open-angle glaucoma or ocular hypertension
    Sall, K
    SURVEY OF OPHTHALMOLOGY, 2000, 44 : S155 - S162
  • [34] Dorzolamide is an effective second-line agent for open-angle glaucoma and ocular hypertension
    不详
    Drugs & Therapy Perspectives, 1997, 10 (7) : 1 - 6
  • [35] Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension
    Lin, Liang
    Zhao, Ying Jiao
    Chew, Paul T. K.
    Sng, Chelvin C. A.
    Wong, Hon-Tym
    Yip, Leonard W.
    Wu, Tuck Seng
    Bautista, Dianne
    Teng, Monica
    Khoo, Ai Leng
    Lim, Boon Peng
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (12) : 1585 - 1593
  • [36] Comparison of dorzolamide and pilocarpine as adjunctive therapy in patients with open-angle glaucoma and ocular hypertension
    Hartenbaum, D
    Maloney, S
    Vaccarelli, L
    Liss, C
    Wilson, H
    Gormley, GJ
    CLINICAL THERAPEUTICS, 1999, 21 (09) : 1533 - 1538
  • [37] A comparison of ocular blood flow in untreated primary open-angle glaucoma and ocular hypertension
    Kerr, J
    Nelson, P
    O'Brien, C
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 126 (01) : 42 - 51
  • [38] Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension
    Fuchsjäger-Mahrl, G
    Wally, B
    Rainer, G
    Buehl, W
    Aggermann, T
    Kolodjaschna, J
    Weigert, G
    Polska, E
    Eichler, HG
    Vass, C
    Schmetterer, L
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (10) : 1293 - 1297
  • [39] Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study
    Blini, Mirella
    Rossi, Gemma Caterina Maria
    Trabucchi, Giuseppe
    Curatola, Maria R.
    David, Alessandro
    Radaelli, Rosella
    Merlo, Giancarlo
    Ratiglia, Roberto
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 57 - 63
  • [40] Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
    Freiberg, Josefine Clement
    von Spreckelsen, Alexander
    Kolko, Miriam
    Azuara-Blanco, Augusto
    Virgili, Gianni
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
12345